Drug Profile
Research programme: STING agonists - LIDDS
Alternative Names: NZ IO; NZ-IO-STING; NZ-Stimulator of Interferon Genes; NZ-STINGLatest Information Update: 01 Aug 2022
Price :
$50
*
At a glance
- Originator LIDDS
- Developer LIDDS; Uppsala University
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants; MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours